2024-12-14 00:39:36
Saudi institutions are optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology. Ekta Torani, chief investment officer of Saudi KBW Venture Capital Company, recently said in Abu Dhabi, United Arab Emirates that with the increasingly close economic and trade ties between the Gulf region and China, the institution is optimistic about China's "huge investment opportunities" in the fields of health care and biotechnology.Market News: Due to weak sales in the United States, Nissan halved the output of its Mexican factory.Zhouming Technology: cooperated with Byte Volcano and Bean Bag to access TTS and big model question-and-answer ability. Zhouming Technology said on the interactive platform that Zhouming Technology cooperated with Microsoft, Tencent, Baidu, Iflytek, Byte Volcano and Bean Bag on the self-developed UniAvatar digital human system. Among them, in May 2024, Zhouming Digital Man was able to access Volcano Engine's TTS capability and bean bag's big model question-and-answer capability, which was suitable for digital man dialogue system and other application scenarios.
Changshu Automobile Accessories: It is planned to invest 22.8 million yuan to set up a joint venture with Antonlin Investment Co., Ltd. Changshu Automobile Accessories announced that the company plans to set up a joint venture with Antonlin Investment Co., Ltd. in Wuhu City, Anhui Province, tentatively named Wuhu Antonlin Intelligent Cockpit System Co., Ltd., with an estimated total investment of 140 million yuan, including a registered capital of 57 million yuan. The company invested 22.8 million yuan, accounting for 40% of the total share capital of Antonglin in Wuhu; Antonglin Investment Co., Ltd. contributed 34.2 million yuan, accounting for 60% of the total share capital of Antonglin in Wuhu. The establishment of the new company will expand the company's industrial layout, improve the company's comprehensive competitive strength and realize the company's strategic plan for sustainable development.Hengrui Pharma: SHR-2173 injection was approved for clinical trial. Hengrui Pharma announced that its subsidiary, Guangdong Hengrui Pharma Co., Ltd., received the Notice of Approval for Clinical Trial of SHR-2173 injection approved and issued by National Medical Products Administration, and agreed to carry out clinical trial. The indication is lupus nephritis. SHR-2173 injection is a therapeutic biological product independently developed by the company, and the research and development expenses have been invested about 45.03 million yuan. The period from research and development to listing of drugs is long, there are many links, and there are uncertain factors. The company will actively promote research and development projects and fulfill its information disclosure obligations.Deputy Director Huang Huabo attended the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group. On December 12, 2024, the 2024 annual discussion meeting of members of the National Medical Security Standardization Working Group was held in Beijing. Huang Huabo, chairman of the working group, member of the party group and deputy director of the National Health Insurance Bureau, attended and spoke. The symposium summarized the work results of the National Working Group on Medical Security Standardization in 2024, and discussed the work in 2025, the five-year development plan of medical security standardization, the framework system and relevant medical insurance standards. Huang Huabo pointed out that in 2024, with the guidance of the National Standards Committee and the support of the bureau party group, all the work of the working group was smoothly promoted through the joint efforts of all members and relevant units inside and outside the bureau. In 2025, the high-quality development of medical insurance put forward higher requirements for medical insurance standardization. It is necessary to further strengthen the sense of responsibility, professionalism and cooperation, accelerate the construction of medical insurance standardization team, and play a supporting role for the high-quality development of medical insurance. (National Medical Insurance Bureau)
Yingli shares: Yingli shares increased capital by 80 million yuan to its holding subsidiary. Yingli shares announced that the company and Shanghai Moqin Intelligent Technology Co., Ltd. increased capital to Nanchang Yingli Precision Manufacturing Co., Ltd., with a total capital increase of 80 million yuan, of which Yingli shares increased capital by 67 million yuan in cash and Shanghai Moqin increased capital by 13 million yuan in cash. After this capital increase, the registered capital of Nanchang Yingli will increase from 20 million yuan to 100 million yuan. After the capital increase is completed, Yingli shares hold 80% of the shares of Nanchang Yingli and Shanghai Moqin holds 20% of the shares. This capital increase does not constitute a connected transaction and does not need to be submitted to the company's shareholders' meeting for consideration.Comments on Hong Kong stocks: Hang Seng Index fell by 2.09%, Hang Seng Technology Index fell by 2.63%, Hong Kong stocks closed, Hang Seng Index fell by 2.09% and Hang Seng Technology Index fell by 2.63%. Domestic insurance stocks and domestic housing stocks were among the top losers, with Sunac China falling more than 8%, and Xpeng Motors, China Pacific Insurance and Zijin Mining falling more than 5%.Barclays: The Central Economic Work Conference released more signals of policy support, which was held in Beijing from December 11th to 12th. The Barclays research team said that the Central Economic Work Conference provided more forward-looking guidance and released more policy support signals. Barclays said that on the whole, the meeting made it clear that "stable economic growth should be maintained next year" and emphasized "implementing more active macro policies" and "vigorously boosting consumption". The agency believes that regulators are more likely to introduce policies in a gradual manner. At the same time, when measuring the rhythm, scale and composition of the next round of measures, we should focus on the development and changes of real estate and stock market. Barclays expects that a more specific financial plan will be announced in March next year. In terms of monetary policy, the meeting proposed to implement a "moderately loose monetary policy". Barclays believes that this change in wording and position has released a positive signal, especially considering the current environment, it is expected that the central bank may cut interest rates significantly in the future. (SSE)
Strategy guide 12-14
Strategy guide 12-14
Strategy guide
12-14
Strategy guide 12-14